Premium
The effect of meloxicam on the pharmacokinetics of beta‐acetyl‐digoxin.
Author(s) -
Degner FL,
Heinzel G.,
Narjes H.,
Turck D.
Publication year - 1995
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1995.tb05794.x
Subject(s) - pharmacokinetics , bioequivalence , digoxin , meloxicam , medicine , crossover study , confidence interval , pharmacology , oral administration , elimination rate constant , randomization , beta (programming language) , clinical endpoint , randomized controlled trial , placebo , heart failure , volume of distribution , alternative medicine , pathology , computer science , programming language
The influence of multiple‐dose administration of meloxicam on the pharmacokinetics of oral beta‐acetyl‐digoxin was studied in 12 healthy male volunteers in a randomized double‐blind two‐way crossover study. The primary endpoint, Cminss, was within the accepted range for bioequivalence, as were Cmaxss and AUCss. The 90% confidence interval and the point estimator of 98.7 for Cminss were within the equivalence range of 0.8‐1.25. MRT and tmax were also unchanged, while the elimination rate constant was decreased slightly by 12%, which is of no therapeutic relevance. It is concluded that co‐treatment with meloxicam has no effect on the pharmacokinetics of oral digoxin.